A compound of Formula, pharmaceutically acceptable salts or stereoisomers thereof: wherein R 1 represents 6- or 7-membered nitrogen-containing saturated fused heterocyclyl, 7-to 12-membered nitrogen-containing spiral heterocyclyl, or 7- to 12-membered nitrogen-containing bridged heterocyclyl, any of which is optionally substituted with 1-4 substituent groups, and R 1 links to pyrimidine ring of Formula via N atom, the substituent groups are selected from halogen atoms, cyano, amino, hydroxyl, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyl C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylcarbonyl or C 1-6 alkoxycarbonyl; R 2 represents hydrogen atom, hydroxyl, amino, cyano, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyl C 1-6 alkyl or C 1-6 alkoxy; R 3 and R 4 each independently represent hydrogen, or C 1-6 alkyl optionally substituted with 1-3 halogen atoms, hydroxyl, carboxyl; m is 0 to 3; Z is hydrogen, or a cation of inorganic base or organic base capable of forming a salt with phosphoric acid; R 5 and R 6 each independently represent hydrogen atom or -Q-R 7, Q represents a bond, or optionally substituted C 1-6 alkylidene, the substituent groups are selected from halogen atoms, hydroxyl, C 1-6 alkyl, amino, cyano, nitro or C 1-6 alkoxy; R 7 is selected from 6- to 14-membered aryl, 5- to 7-membered heterocyclyl or 8- to 10-membered fused cyclyl, any of which is optionally substituted with 1-4 substituent groups, the substituent groups are selected from halogen atoms, hydroxyl, C 1-6 alkyl, halo C 1-6 alkyl, carboxyl C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, halo C 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, cyano, nitro, C 1-6 alkylcarbonyl, sulfonylamino or C 1-6 alkylsulfonylamino. wherein R 1 represents 6- or 7-membered nitrogen-containing saturated fused heterocyclyl, 7-to 12-membered nitrogen-containing spiral heterocyclyl, or 7- to 12-membered nitrogen-containing bridged heterocyclyl, any of which is optionally substituted with 1-4 substituent groups, and R 1 links to pyrimidine ring of Formula via N atom, the substituent groups are selected from halogen atoms, cyano, amino, hydroxyl, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyl C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylcarbonyl or C 1-6 alkoxycarbonyl; R 2 represents hydrogen atom, hydroxyl, amino, cyano, C 1-6 alkylamino, di(C 1-6 alkyl)amino, C 1-6 alkyl, halo C 1-6 alkyl, hydroxyl C 1-6 alkyl or C 1-6 alkoxy; R 3 and R 4 each independently represent hydrogen, or C 1-6 alkyl optionally substituted with 1-3 halogen atoms, hydroxyl, carboxyl; m is 0 to 3; Z is hydrogen, or a cation of inorganic base or organic base capable of forming a salt with phosphoric acid; R 5 and R 6 each independently represent hydrogen atom or -Q-R 7, Q represents a bond, or optionally substituted C 1-6 alkylidene, the substituent groups are selected from halogen atoms, hydroxyl, C 1-6 alkyl, amino, cyano, nitro or C 1-6 alkoxy; R 7 is selected from 6- to 14-membered aryl, 5- to 7-membered heterocyclyl or 8- to 10-membered fused cyclyl, any of which is optionally substituted with 1-4 substituent groups, the substituent groups are selected from halogen atoms, hydroxyl, C 1-6 alkyl, halo C 1-6 alkyl, carboxyl C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, halo C 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, cyano, nitro, C 1-6 alkylcarbonyl, sulfonylamino or C 1-6 alkylsulfonylamino.